What is Rosuvastatin 

A lipid-lowering drug, that is, with activity to lower levels of the harmful LDL cholesterol and anti-inflammatory, fully synthetic statin.

Take only under medical supervision

Statins have irrefutably demonstrated their effectiveness in reducing cardiovascular risk.

Rosuvastatin is a selective inhibitor of HMG‐CoA reductase. The cholesterol‐lowering effect of the drug manifests by blocking 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, a rate controlling enzyme in the metabolic pathway that produces cholesterol. Of particular note, rosuvastatin has the highest affinity and highest inhibitory effect against HMG‐CoA reductase compared to other statin drugs, effectively reducing LDL (1).

 In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvastatin/ezetimibe was significantly more effective than rosuvastatin monotherapy (including at double the dose of rosuvastatin) or simvastatin/ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C) and total cholesterol in adults with hypercholesterolemia (2).

Regarding the comparison between rosuvastatin and atorvastatin, this study confirmed that the efficacy of rosuvastatin was superior to that of atorvastatin (3) and 10mg rosuvastatin were shown to be more effective than 20 mg atorvastatin in lowering serum lipid levels and elevating the ABI  ( an atherosclerosis rating scale) (4).

Like all drugs it can cause side effects. Always ask the physician.

Rosuvastatin studies

Molecular Formula: C₂₂H₂₈FN₃O₆S

Molecular Weight: 481.54

CAS: 287714-41-4

UNII  413KH5ZJ73

EC Number: 

DSSTox Substance ID: DTXSID8048492

Synonyms: 

• (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid
• Creston
• (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

References_____________________________________________________________

(1) Jin X, Kim MH, Han KH, Hong SJ, Ahn JC, Sung JH, Cho JM, Lee HC, Choi SY, Lee K, Kim WS, Rhee MY, Kim JH, Hong SP, Yoo BS, Cho EJ, Lee JH, Kim PJ, Park CG, Hyon MS, Shin JH, Lee SH, Sung KC, Hwang J, Kwon K, Chae IH, Seo JS, Kim H, Lee H, Cho Y, Kim HS. Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1835-1845. doi: 10.1111/jch.13893.

(2) Lamb YN. Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs. 2020 Aug;20(4):381-392. doi: 10.1007/s40256-020-00421-1. 

(3) Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. Herz. 2020 Sep;45(6):594-602. English. doi: 10.1007/s00059-018-4767-2. 

(4) Liping Z, Xiufang L, Tao Y, Baomin Z, Houshuai T. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2203-2208.